anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a polymer thin film having &gt;100 nm thickness in a short time by simple operation and to provide an external preparation for skin comprising thin-film coated powder.  &lt;P&gt;SOLUTION: A cationic polymer in which a part or all of nitrogen atoms of a polyamine compound are quaternized with a compound represented by general formula (I) (wherein, X is a halogen atom; n is an integer of 1-20; and m is an integer of 1-20) is provided. Cationic polymer-adsorbing powder is obtained by adsorbing the cationic polymer on the surface of base powder having a negative value of ζ potential. The thin-film coated powder is prepared by polymerizing a monomer molecule on the surface of the cationic polymer-adsorbing powder and forming the thin film thereon. The external preparation for skin comprises the cationic polymer-adsorbing powder or thin-film coated powder.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for preparation and use of flaviviruses and their vaccines.  &lt;P&gt;SOLUTION: There is provided flaviviruses including one or more hinge region mutations that reduce viscerotropism of the flaviviruses. In one example of a chimeric flavivirus, the chimera includes a capsid and non-structural proteins of a first flavivirus and a pre-membrane and envelope proteins of a second flavivirus or Dengue virus including envelope protein mutations that reduce viscerotropism of the chmeric flavivirus. In the case of the Dengue virus, the mutation may be, for example, 202 or 204-site lysine of Dengue envelope amino acid. The amino acid may be replaced by arginine.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
PURPOSE:To obtain a vitamin E-containing composition not freezing even by preservation at a low temperature. CONSTITUTION:A vitamin E-containing composition comprises a vitamin E and fats and oils containing &gt;=40% alpha-linolenic acid as a constituent fatty acid. Perilla oil may be cited as the fats and oils containing &gt;=40% alpha-linolenic acid as a constituent fatty acid. The amount of the fats and oils mixed is preferably 0.2-10 pts.wt. based on 1 pt.wt. of the vitamin E.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a bad breath-reducing composition capable of effectively preventing or reducing the bad breath, and having good flavor enabling the composition to be utilized for food and drink.  &lt;P&gt;SOLUTION: The bad breath-reducing composition contains cocoa as an active ingredient. Preferably, the bad breath-reducing composition contains at least one kind selected from plant extracts such as champignon essence, spices such as nutmeg, herbs such as parsley, essential oils such as peppermint, sweeteners such as sorbitol, chitin, chitosan, and the like, as other active ingredient. The content of the cocoa is preferably 0.01-50 mass%. The bad breath-reducing composition is preferably formed into a shape of gargle, gum, candy, chocolate, drink, or the like.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
The present invention provides an isolated nucleic acid sequence encoding saitohin (STH), an isolated nucleic acid sequence that hybridizes to said sequence, and a purified protein encoded by said nucleic acid sequences. The present invention also provides a purified STH protein, and a method of making STH protein. The present invention is further directed to an antibody specific for STH, and a method for producing said antibody. Additionally, the present invention discloses a vector comprising a nucleic acid sequence encoding STH, a host cell transformed with said vector, and transgenic nonhuman animals. The present invention further provides methods for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease, and for assessing said subject&#39;s prognosis. Finally, the present invention discloses kits for determining whether a subject has, or is at increased risk for developing, a neurodegenerative disease.
The invention discloses a Y-region beauty device which can easily improve female vagina or inflammation of the part by a user. The Y-region beauty treatment equipment comprises a cartridge mounting part, a fumigation cartridge and a heat generating part. A cartridge insertion portion is formed at one side surface of the cartridge mounting portion. The fumigation cartridge is inserted and mounted in the cartridge insertion part, and the fumigation generating substance exists in a solid or liquid state in the fumigation cartridge. The heat generating part is disposed adjacent to the cartridge mounting part and supplies heat to the fumigation cartridge, so that fumigation of the fumigation cartridge can be performed. Thus, the Y-site beauty apparatus discharges the fumigant to the vagina of the female, so that the user can easily and conveniently prevent inflammation of the vagina, skin sensitization, improve malodor, etc. just by placing the Y-site beauty apparatus in front of the user&#39;s vagina.
FIELD: biotechnology, immunology. SUBSTANCE: invention relates to hybridoma technology. Hybridoma is obtained by fusion of murine myeloma line NSO and murine splenocytes line BALB/c immunized with inactivated Ebol&#39;s virus. Hybridoma produces monoclonal antibodies isotype IgG to Ebol&#39;s virus used as a component of IFA-system for indication and identification of Ebol&#39;s virus. The resolution capacity of test-system based on monoclonal antibody is estimated to be 1.0 x 10 3  PFU x cm -3 . The use of hybridoma provides to obtain monoclonal antibodies raised to GP protein of Ebol&#39;s virus. EFFECT: hybridoma indicated above, valuable properties. 1 dwg, 3 tbl
In the invention, phytochromes are activated in focuses such as tumors, vascular patches and skin diseases, in a fixed-point and fixed-quantity way by a specific means through the utilization of the specific affinity action of the phytochromes on the focuses, the decomposition reaction of H2O2 is catalyzed by the phytochromes to generate &lt;1&gt;O2, and the apoptosis or the necrosis of pathological cells is caused, thereby achieving the purpose of treating the diseases. A corresponding serial novel drug is screened, developed and used for CDT (Chemodynamic Therapy) or RCDT (Radiochemodynamic Therapy). The invention relates to the serial novel drug which is used for CDT and RCDT. The serial novel drug can catalyze the chemical reaction of decomposing the H2O2 to generate the &lt;1&gt;O2, does not have obvious side effect on the normal tissues and organs of a human body, and meanwhile, has the capability of affiliating the focuses. The phytochromes are used as a catalyst, and the acting mechanism, the usage, the therapeutic effect and the like of the phytochromes are completely different from those of traditional photo-dynamic therapy. Oxygen and visual light are not needed, and a completely independent novel drug series can be formed.
FIELD: agriculture, veterinary immunology, helminthology. SUBSTANCE: preparation includes L-arginine amino acid and immunomodulator as sodium nucleinate, and Hanks&#39; solution at their corresponding ratios. Said preparation provides high therapeutic efficiency in case of hepatosis and nematodiasis along with improved immune status and body resistance in animals. Preparation is positively approved. EFFECT: higher efficiency of therapy. 2 ex, 2 tbl
FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to the improved method of preparing final adduct products of condensation that are Schiff&#39;s bases and comprise protein eliciting useful activity in animals and aromatic o-hydroxyaldehyde. Method involves the addition reaction in aqueous medium at pH 7.0 or above to form reaction mixture under conditions providing the effectiveness of the indicated condensation reaction carrying out up to its completion. Method involves the more rapid removal of about 97.0-99,9% of water by mass, preferably about 98.0-99.0% of water by mass presenting or forming in the process of the condensation reaction as compared with method of drying under environment conditions and providing the maintenance of condensation reagents integrity and final adduct product. Preferable aromatic o-hydroxyaldehydes involve: o-vanillin, salicylic aldehyde, 2,3-dihydroxybenzaldehyde, 2,6-dihydroxybenzaldehyde, 2-hydroxy-3-ethoxybenzaldehyde or pyridoxal. Very wide range of proteins can be used. The improved method provides yields above 90% and quantitative conversion of aldehyde and protein to the condensed adduct. EFFECT: improved method of preparing. 15 cl, 8 tbl, 10 dwg
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an iron oxide complex for administration to a mammalian subject.  &lt;P&gt;SOLUTION: A composition, and methods of producing and using the composition are provided for an enhanced magnetic resonance imaging agent and a hematinic agent. The agents comprise a carboxyalkylated reduced polysaccharide-coated ultrafine superparamagnetic iron oxide. The method of using carboxymethyl-reduced dextran as a plasma extender is also provided. The invention further provides, as another embodiment, a method for preparing the iron oxide complex coated with a reduced polysaccharide.  &lt;P&gt;COPYRIGHT: (C)2011,JPO&amp;INPIT
A thyreotropic hormone which has the property of causing the development of the parenchyma and the shrinkage of the colloid of the thyroid gland, is obtained from aqueous extracts of the anterior lobe of the hypophysis by treatment thereof with an albumen precipitant and separation of the active substance from the precipitant.  The mother liquors from the precipitation contain the gonadotropic hormone and may be worked up for the recovery thereof, as described in Specifications 288,132 and 313,924, [both in Class 81 (i), Disinfecting &amp;c.].  Suitable precipitating agents are picric acid, sulpho salicylic acid, trichloracetic acid, heavy metal salts such as lead acetate, or colloids such as hydroxide of iron or alumina.  The precipitating agent may be removed with organic solvents such as alcohol and ether or in the case of lead acetate alcohol mixed with acetic acid.  Precipitates such as iron hydroxide are taken up by dilute acid, and the hormone obtained therefrom by treatment with albumen precipitants soluble in organic solvents.  The purification may be continued by repeated precipitation and by bringing the solution to the isoelectric point to cause flocculation of albuminous substances.
PURPOSE: To control the level of nerve growth factor(NGF) of central nervous system by administering an effective amount of cytokine. CONSTITUTION: The NGF level of a central nervous system is controlled by administering an effective amount of a cytokine to increase the NGF synthesis, a cytokine to lower the NGF synthesis or a substance indirectly varying the NGF level by varying the cytokine level. The cytokine effective for increasing the NGF synthesis is e.g. interleukin-1, fibroblast growth factor, tumor growth factor αand β and platelet-originated growth factor, and the substance to vary the cytokine level is e.g. an IL-1 inhibitor such as glucocorticoid (e.g. dexamethasone). This procedure is effective for the treatment of nervous disorder caused by the damage of central nervous system by surgical operation, ischemia, sensitive tumor or a toxic agent, congenital learning disability and degenerative disorder of nerve, especially dementia such as Alzheimer&#39;s disease.
NEW MATERIAL:The peptide of formula [A is Gly or Ala; B is Phe or alkyl- Phe; D is Met, Met-sulfoxide or Leu; E is Ser or Tyr; F is Gly or Glu; G is Ala or Val; Y is OH or NR&lt;1&gt;R&lt;2&gt; (R&lt;1&gt; and R&lt;2&gt; are H or alkyl); the steric configuration of the amino acid residues is D, L or DL]. USE:An analgesic agent. PROCESS:The objective peptide can be prepared using either liquid-phase or solid- phase peptide synthesis process, by protecting the amino groups and carboxyl groups having no participation in the reaction, extending the N-terminal of the starting raw material successively with required peptide chains by the synthesis process such as mixed acid anhydride process, axide process, etc. until the last peptide chain is bonded to the chain, and removing the protecting groups by conventional process (e.g. treatment with trifluoroacetic acid, reduction, etc.).
The invention comprises azabenzimidazoles of the general formula: &lt;FORM:0945147/C2/1&gt; and their physiologically tolerable acid addition salts wherein A represents a C1-3 alkylene radical R a dialkylamino (C1-3) group or a pyndidino, piperidino, piperazino or morpholino group, R1 represents a hydrogen atom, a hydroxyl or mercapto group, a C1-5 alkoxy group or a C1-5 alkylmercapto group and &lt;FORM:0945147/C2/2&gt; represents an unsubstituted or nitro substituted pyridine ring.  The compounds may be prepared by subjecting an amino pyridine, containing a tertiary amino alkylamino group in a position ortho to the amino group or a substituent convertible into or replaceable by such a group, to ring closure with an alkanoic acid or a reactive functional derivative thereof such as an ester or imino ether thereof or with a carbonic or thiocarbonic acid derivative to form an azabenzimidazole ring and if necessary converting or replacing such a group. The alkanoic acid may be replaced by the alkane aldehyde or a functional derivative thereof and the product oxidised.  The compounds may also be prepared by introducing into the 1-position of an azabenzimidazole directly or in stages of tertiary amino alkyl group substituents may be introduced into the imidazole nucleus of the products or one substituent replaced by or converted into another.  The nitro group may be introduced into the pyridine ring.  2 - (b  - Diethylaminoethylamino) - 3 - amino - 5 -nitro pyridine is prepared by condensing 2-chloro-3,5-dinitro pyridine with diethylaminoethylamine to give 2-(b -diethylaminoethylamino) -3,5-dinitro-pyridine and reducing the 3- nitro group.  Similarly are prepared 2-(b -dimethylamino - ethylamino) -3-amino-5-nitropyridine and -3,5-dinitropyridine;  3-amino- and 3-nitro-4-(b -diethylaminoethylamino) - pyridines; 3-amino-and 3-nitro-4-(b -dimethylaminoethylamino) - pyridines, 3-amino- and 3-nitro-4-(b -morpholinoethylamino)-pyridines; 2-(b -diethylaminoethylamino) -3-amino- and -3-nitro-pyridines; 2-(b -dimethylaminoethylamino) -3-amino-and -3-nitro-pyridines; -4-(b -dimethylaminoethylamino) -3-amino -5-nitro- and -3,5-dinitro-pyridines. 5(6)-Nitro -7(4)-azabenzimidazole is prepared by ring closure with formic acid of 2,3-diamino-5-nitro pyridine in turn prepared by reacting 2-chloro-3,5-dinitropyridine with ammonia to give 2-amino -3,5-dinitro pyridine and reducing the 3-nitro group.  Pharmaceutical compositions comprise azobenzimidazoles of the invention in admixture with or in conjunction with a pharmaceutical carrier suitable for enteral, parenteral or topical administration. Compositions may take the form of tablets, dragees, salves, creams, solutions, suspension or emulsions and may contain other therapeutically useful substances.
&lt;P&gt;PROBLEM TO BE SOLVED: To solve problems of a conventional carbohydrate microneedle wherein the needle part is broken in a part around a weak bonded part between the needle part and a base plate part and the needle part cannot stick in the skin when the needle part is inserted into the skin because the needle part and the base plate part are made of different materials and the bond between the needle part and the base plate part is weak, and wherein the practical utility is extremely impaired because a medicament, etc. is mounted on the upper surface of the needle part only, and as a result, the size of the medicament etc. is limited and the dose of the medicament to the skin is limited, or the like.  &lt;P&gt;SOLUTION: The carbohydrate microneedle is composed of one or a plurality of carbohydrate microneedles disposed and integrated in the shape of a comb on a side face of a microneedle attaching margin. The attaching margin is welded to a side end or biting part on the upper surface of the base plate made of a different material. As a result, the strength in the vicinity of the root of the needle part is high, so that the effect of easy sticking in the skin, and the effect of mounting a larger quantity of medicaments on the upper surface of the needle part and the upper surface of the attaching margin can be provided.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
FIELD: medicinal industry, pharmacy. SUBSTANCE: invention relates to production of drugs comprising nitroglycerol and used for acute stenocardia attacks arresting. In the process of preparing antianginal medicinal agent inert pharmaceutical filling agent is wetted with nitroglycerol solution in polar organic solvent and then with binding agent solution, dried, subjected for dry granulation and tableted in rotor tablet-press. Components are taken in the following ratio, wt.-%: nitroglycerol, 0.5-1.2; inert pharmaceutical filling agent, 92.8-98.8; binding agent, 0.5-5.0; stearic acid and/or calcium or magnesium stearates, 0.2-1.0. Tablet mass is 0.04-0.09 g. Decomposition index of nitroglycerol tablets is less 60 s, they are stable at storage in opened packages. Tablet quality satisfies to requirements of Pharmacopoeia and pharmacopoeia article &#34;Tablets Nitrocardine sublingual&#34;. EFFECT: improved method of preparing, valuable properties of tablets. 7 cl, 10 tbl
Delivery of glial cell line-derived neurotrophic factor (GDNF) has provided benefits to Parkinsonian patients and is currently being tested in a Phase 1/2a clinical trial for ALS patients. However, chronic trophic factor delivery prohibits dose adjustment or shut off in the event of side effects. To address this, the Inventors engineered a stably integrating, third-generation doxycycline-regulated vector, allowing inducible and reversible expression of a therapeutic molecule. Human iPSC-derived neural progenitors were stably transfected with the vector, expanded and transplanted into the adult mouse brain. The Inventors observed that the addition and withdrawal of doxycycline led to GDNF expression that could be induced and reversed multiple times, demonstrating that doxycycline can penetrate the graft and regulate transgene expression in vivo. The Inventors&#39; findings provide a proof of concept for combining gene and stem cell therapy for effective modulation of ectopic protein expression in transplanted cells.
PURPOSE:To provide a producing method of an apatite powder having a controlled composition without changing pH by improving the defects in aq. solution method by conventional technology. CONSTITUTION:The apatite is deposited by heating a mixed aq. solution of two kinds of a water soluble calcium complex inert to free phosphate ion and an water soluble phosphate at &gt;=30 deg.C. Air, oxygen or hydrogen peroxide can be introduced to complete the reaction. A chelete salt such as ethylenediaminetetraacetic acid calcium salt, nitrilotriacetic acid calcium salt, cyclohexanediaminetetraacetic acid calcium salt, glycol ether diamimetetraacetic acid calcium salt, diethylenetriaminepentaacetic acid calcium salt or the like is exemplified as the water soluble calcium complex inert to free phosphate ion. The apatite powder is preferably used for producing an artificial bone material, artificial tooth material, adsorbing material or the like.
PURPOSE: To obtain a polymer mixture, comprising a polyionic polypeptide, a high-molecular weight polyanion and a highly charged polyanion and capable of providing a pH-dependent phase change in an aqueous solution and imparting the improved dispersibility and increased smoothness and uniformity to a cosmetic preparation. CONSTITUTION: This aqueous composition comprises water and a ternary polymer mixture of (A) a polyionic polypeptide, e.g. a protein, especially a blood serum albumin, (B) a high-molecular weight polyanion having about &gt;=100,000, preferably about 1,000,000 to about 10,000,000 molecular weight, e.g. a polynucleotide or a polycarboxylate, especially hyaluronan or its derivative and (C) a highly charged polyanion having about &lt;3pKa, especially about &lt;1.5pKa in an amount so as to provide about &lt;1,000, especially about 100 to about 350 equiv. weight of acidic groups, e.g. a polysulfate or a polysulfonate, especially dextran sulfate. The aqueous composition is capable of providing a pH-depefident phase change in an aqueous solution (e.g. a change in light transmittance).  The preferred amount of the respective formulated components are about 0.1 to about 20wt.% of the component A and about 0.05 to about 1wt.% each of the components B and C.
The invention provides high concentration pidotimod oral liquid, which can promote human body immune response, effectively reduces times and degree of acute attack of infections caused by bacteria or virus, shortens disease course, can serve as auxiliary medicine antibiotic of acute infection and belongs to the field of medicines. The oral liquid contains constitutions of pidotimod, chemical stabilizer, a potential of hydrogen (pH) adjusting agent, a flavoring agent and the like.  Tris-(hydroxymethyl)-aminomethane is used as the pH adjusting agent. The oral liquid is stable in quality and convenient to store for a long time. By means of quantitative proportioning and synergistic effect of all constitutions, when the concentration of the oral liquid is improved, simultaneously the stability and taste of the oral liquid are obviously improved. The oral liquid doesn&#39;t contain sugar capable of being absorbed and used by human bodies and is suitable for the old and children.
The target population consists of adult patients aged 25-40, with posterior compound proximal carious cavities (ICDS score 4 or 5) in molars. The interventions under investigation include three different separation systems: the Resin ring (DR-Resin ring, Egypt), Elliot separator (Pfingst \&amp; Co, USA), and Stainless Steel Metal ring (TOR VM ring, Russia). These systems will be compared to a Nickel titanium 3D-fusion ring (Garrison, USA). The primary outcomes assessed are proximal contact tightness and form/contour, measured visually according to FDI criteria, with scoring systems adapted from Hickel et al. (2023). Secondary outcomes, such as patient comfort (measured by a pain rating scale), and the emergence profile (assessed via bitewing radiographs), will also be considered. Data will be collected immediately postoperatively (T0), at 30 days (T1), and after 6 months (T2). The study will be conducted as a randomized clinical trial. The null hypothesis suggests that there will be no significant differences in proximal contact tightness or contour across the different separation systems used.
To provide a medication management system, a management server, and a control program for the management server with which it is possible to appropriately manage medication to patients and reduce the burdens of caregivers, etc. related to the management of medication to patients.SOLUTION: A medication management system comprises a management server 152 and a caregiver terminal 352. The caregiver terminal 352 transmits a notification of medication completed to the management server 152 upon accepting input of completion of medication. The management server 152 stores, in a database, patient identification information, patient medicine information, and patient medication information in association. The management server 152 stores the fact of medication completed in the database upon receiving the notification of medication completed. The management server 152 notifies the point of contact of a manager about a forgotten medication to a patient, when the fact of medication completed is not stored in the database even after an elapse of the time determined on the basis of the patient&#39;s medication information.SELECTED DRAWING: Figure 1